PIA
BPMC

Piedmont Investment Advisors’s Blueprint Medicines BPMC Stock Holding History

Piedmont Investment Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-718
Closed -$46K – 1198
2018
Q2 		$46K Buy
+718
New +$57.1K ﹤0.01% 1316

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 17.47% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Piedmont Investment Advisors's BPMC Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Blueprint Medicines (BPMC) in Q3 2018, closing a stake of 718 shares — an estimated $46K sold.

Piedmont Investment Advisors first reported a position in BPMC in Q2 2018 and held it in 1 quarter. The position peaked at $46K in Q2 2018. 188 funds tracked by Wall St. Rank hold BPMC as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Blueprint Medicines position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 718 Blueprint Medicines shares in Q3 2018, an estimated $46K.
  • Piedmont Investment Advisors first reported a position in Blueprint Medicines in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Blueprint Medicines position peaked at $46K in Q2 2018.
  • 188 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.